Tag Archive for: PSMA
APVO442: A Promising Preclinical Candidate in the Fight Against Prostate Cancer
/0 Comments/in Immunotherapy, Preclinical Research/by MaxA Seattle-based biotech, is stepping up with APVO442, a promising preclinical bispecific antibody aimed at transforming prostate cancer treatment by unleashing the body’s immune system against tumors with greater precision and fewer side effects. Built on proprietary ADAPTIR-FLEX platform, APVO442 is designed to target prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer […]
Phase 1 Trial for ART-101, a Novel Radioligand Targeting PSMA in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Recruiting: ABBV-969, A Novel Bispecific Antibody Drug Conjugate for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase I Clinical Trial of AZD2284, AZD2287, and AZD2275
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial Recruiting: Bispecific Antibodies JNJ-87189401 and JNJ-78278343
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxCTT2274: A Potential Game-Changer for Metastatic Prostate Cancer Treatment…start hating the word “potential”
/0 Comments/in Preclinical Research/by MaxPromising Results for 177Lu-PSMA-I&T in Prostate Cancer Treatment
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxARX517 Achieves Key Safety and Efficacy Milestones in Phase 1/2 Trials for Metastatic Castration-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial theranostics
Latest Posts
- UPDATE: Phase 2 Results for 177Lu-DGUL Look Very Promising September 5, 2025
- Another Trial Supports Low-Dose Abiraterone Acetate in mCRPC September 5, 2025
- Follow-up of ARCHES Trial Shows Extended Survival September 4, 2025
- IND Required for ITC-6146RO for Solid Tumors Overexpressing the B7-H3 Protein September 2, 2025